Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to $100.1 billion.

  • Takeda Pharmaceutical's Liabilities and Shareholders Equity rose 74.34% to $100.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $388.5 billion, marking a year-over-year decrease of 366.21%. This contributed to the annual value of $93.5 billion for FY2025, which is 1071.72% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Liabilities and Shareholders Equity of $100.1 billion as of Q4 2025, which was up 74.34% from $98.2 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Liabilities and Shareholders Equity registered a high of $122.0 billion during Q1 2021, and its lowest value of $93.4 billion during Q1 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $103.6 billion (2023), whereas its average is $104.6 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Liabilities and Shareholders Equity surged by 359.58% in 2021, and later plummeted by 1443.13% in 2022.
  • Over the past 5 years, Takeda Pharmaceutical's Liabilities and Shareholders Equity (Quarter) stood at $111.7 billion in 2021, then dropped by 14.43% to $95.6 billion in 2022, then increased by 0.66% to $96.2 billion in 2023, then grew by 3.27% to $99.4 billion in 2024, then increased by 0.74% to $100.1 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $100.1 billion for Q4 2025, versus $98.2 billion for Q3 2025 and $96.8 billion for Q2 2025.